Open Access
Med Buccale Chir Buccale
Volume 19, Number 2, avril 2013
Page(s) 113 - 117
Section Observations cliniques / Case reports
Published online 13 February 2013
  1. Estimation nationale issue d'une modélisation des données d'incidence observées jusqu'en 2005 : « Projection de l’incidence et de la mortalité par cancer en France en 2010 ; fiche Myélome multiple et maladies immunoprolifératives INVS » : [Google Scholar]
  2. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, Trichopoulos D. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007;120:40-61. [CrossRef] [PubMed] [Google Scholar]
  3. Carli PM, Bailly F, Tavernier C, Milan C, Heudes D, Lavault JF. Multiple myeloma: epidemiological features in a well-defined population in Burgundy, France. Int J Epidemiol 1989;18:330-3. [CrossRef] [PubMed] [Google Scholar]
  4. Dieye M, Quénel P, Goria S, Blateau A, Colonna M, Azaloux H. Étude de la répartition spatiale des cancers possiblement liés à la pollution des sols par les pesticides organochlorés, en Martinique (27 p). Institut de veille sanitaire 2009. [Google Scholar]
  5. Stoopler ET, Vogl DT, Stadtmauer EA. Medical management update: multiple myeloma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:599-609. [CrossRef] [PubMed] [Google Scholar]
  6. Mozaffari E, Mupparapu M, Otis L. Undiagnosed multiple myeloma causing extensive dental bleeding: report case and review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:448-53. [CrossRef] [PubMed] [Google Scholar]
  7. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40. [PubMed] [Google Scholar]
  8. Lae ME, Ventio EF, Inwards CY, Unni KK, Nascimento AG. Myeloma of the jaw bones: a clinicopathologic study of 33 cases. Head Neck 2003;25:373-81. [CrossRef] [PubMed] [Google Scholar]
  9. Epstein JB, Voss NJ, Stevenson-Moore P. Maxillofacial manifestations of multiple myeloma. An unusual case and review of the literature. Oral Surg Oral Med Oral Pathol 1984;57:267-71. [CrossRef] [PubMed] [Google Scholar]
  10. Pisano JJ, Coupland R, Chen SY, Miller AS. Plasmacytoma of the oral cavity and jaws: a clinicopathologic study of 13 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:265-71. [CrossRef] [PubMed] [Google Scholar]
  11. Lambertenghi-Deliliers G, Bruno E, Cortelezzi A, Fumagalli L, Morosini A. Incidence of jaw lesions in 193 patients with multiple myeloma. Oral Surg Oral Med Oral Pathol 1988;65:533-7. [CrossRef] [PubMed] [Google Scholar]
  12. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20. [CrossRef] [PubMed] [Google Scholar]
  13. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54. [CrossRef] [PubMed] [Google Scholar]
  14. Lee SH, Huang JJ, Pan WL, Chan CP. Gingival mass as the primary manifestation of multiple myeloma: report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:75-9. [CrossRef] [PubMed] [Google Scholar]
  15. Torres Urbina CA, Arellano Flores AM, Vazquez Salvador JL, Barbosa Ibarra AA, Fernandez Lopez RG, Aldape Barrios BC. Plasmocytome mandibulaire révélateur d’un myélome multiple. Présentation d’un cas. Med Buccale Chir Buccale 2010;16:183-8. [CrossRef] [EDP Sciences] [Google Scholar]
  16. Tsuda H, Yamasaki H, Tsuji T, Yokoo E. Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma. Int J Hematol 2012;95:706-10. [CrossRef] [PubMed] [Google Scholar]
  17. Larocca A, Cavallo F, Mina R, Boccadoro M, Palumbo A. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncol 2012;8:1223-38. [CrossRef] [PubMed] [Google Scholar]
  18. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foà R, Hellmann A, Dimopoulos M, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥ 65 years old with relapsed or refractory multiple myeloma. Int J Hematol 2012;96:254-62. [CrossRef] [PubMed] [Google Scholar]
  19. Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. Acta Clin Belg 2011;66:371-5. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.